1. La révolution des anti-thrombotiques M M. SAMAMA, J. CONARD, M-H. Horellou Service d’Hématologie Biologique, Hôtel-Dieu, Paris - France Pr Lacombe & Pr Fontenay G roupe I nterdisciplinaire T rousseau sur les A ntithrombotiques
2.
3. Médicaments antithrombotiques Plaquettes Facteurs de coagulation Activation de la coagulation THROMBINE Fibrinogène FIBRINE F Xa libre F Xa lié Riva Heparines et Fonda Dabi Antiplaquettaires Anticoagulants Thrombolytiques
26. Prophylaxie PTH PTG Traitement TVP EP FA sélection des patients Syndromes coronaires aiguës Prophylaxie en milieu médical Etudes des influences médicamenteuses et alimentaires Evaluation des nouveaux anticoagulants
45. ACS-TIMI 46 (Anti-Xa Therapy to Lower cardiovascular events in additional to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome 3491 patients were randomised in a 1:1:1 manner to placebo, rivaroxaban once a day, or rivaroxaban twice a day
46. Clinically significant bleeding (TIMI major, TIMI minor, or requiring medical attention), categorised by total daily dose for the entire population, stratum 1, and stratum 2